Skip to main content
European Commission logo
Enterprise Europe Network

Turkish Biotech SME Consortium Leader Search for Spanish Entities for the EUREKA Türkiye-Spain Call for R&D Projects

Summary

Profile Type
  • Research & Development Request
POD Reference
RDRTR20250213019
Term of Validity
13 February 2025 - 13 February 2026
Company's Country
  • Turkey
Type of partnership
  • Research and development cooperation agreement
Targeted Countries
  • All countries
Contact the EEN partner nearest to you for more information.
Find my local partner

General information

Short Summary
Turkish Biotech SME is looking for spanish partners for submitting a proposal for Türkiye and Spain call for R&D projects
Full Description
This project aims to develop a 3D bioprinted tumor model using patient-derived cells and ECM-based bioinks to enhance cancer drug screening, tumor progression studies, and immunotherapy research. Key objectives include:
• Development of ECM-based bioinks optimized for tumor tissue engineering.
• Fabrication of 3D bioprinted tumor models that replicate in vivo-like conditions.
• Implementation of high-throughput drug screening methods for chemotherapy, immunotherapy, and targeted therapies.
• Integration with organ-on-a-chip technology to model tumor metastasis and drug responses.
Advantages and Innovations
Traditional 2D cell cultures and animal models fail to accurately replicate the complex tumor microenvironment, leading to low translatability of preclinical drug testing results. Extracellular Matrix (ECM)-supported 3D bioprinting offers a more physiologically relevant alternative, allowing for the recreation of the tumor microenvironment, cellular interactions, and drug resistance mechanisms in a laboratory setting.
Stage of Development
  • Concept stage
Sustainable Development Goals
  • Goal 9: Industry, Innovation and Infrastructure
IPR description
The company is looking for spanish profit organisations who can take part as a project partner for 1-2 of following tasks:
• Development of ECM-based bioinks optimized for tumor tissue engineering.
• Fabrication of 3D bioprinted tumor models that replicate in vivo-like conditions.
• Implementation of high-throughput drug screening methods for chemotherapy, immunotherapy, and targeted therapies.
• Integration with organ-on-a-chip technology to model tumor metastasis and drug responses.

Partner Sought

Expected Role of a Partner
• Development of ECM-based bioinks optimized for tumor tissue engineering.
• Fabrication of 3D bioprinted tumor models that replicate in vivo-like conditions.
• Implementation of high-throughput drug screening methods for chemotherapy, immunotherapy, and targeted therapies.
• Integration with organ-on-a-chip technology to model tumor metastasis and drug responses.
Type and Size of Partner
  • SME <=10
  • SME 50 - 249
  • SME 11-49
Type of partnership
  • Research and development cooperation agreement

Call details

Framework program
  • Eureka
Call title and identifier
Türkiye and Spain call for R&D projects
Coordinator required
No
Deadline for EoI
Deadline of the call

Dissemination

Market keywords
  • 05007007 - Other medical/health related (not elsewhere classified)
Targeted countries
  • All countries